---
title: "600521.SH (600521.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600521.SH/news.md"
symbol: "600521.SH"
name: "600521.SH"
parent: "https://longbridge.com/en/quote/600521.SH.md"
datetime: "2026-05-19T16:14:07.552Z"
locales:
  - [en](https://longbridge.com/en/quote/600521.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600521.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600521.SH/news.md)
---

# 600521.SH (600521.SH) — Related News

### [Huahaipharm's "Ice and Fire": A 76% drop in annual net profit, a 36% surge in a single quarter behind the non-recurring truth | Financial Report Anomaly Perspective](https://longbridge.com/en/news/284714608.md)
*2026-04-30T07:03:13.000Z*
> Huahaipharm's financial report released in 2025 shows a 76% plunge in net profit attributable to shareholders, a 10.06% 

### [Huahaipharm: Net profit of 404 million yuan in the first quarter of 2026, a year-on-year increase of 35.90%](https://longbridge.com/en/news/284544866.md)
*2026-04-29T10:21:42.000Z*
> Huahaipharm announced that the operating revenue for the first quarter of 2026 was 2.335 billion yuan, a year-on-year de

### [Huahaipharm: Plans to spin off its controlling subsidiary Huaotai for an IPO](https://longbridge.com/en/news/284544637.md)
*2026-04-29T10:21:07.000Z*
> Huahaipharm announced that in order to promote the development of its biological innovative drug R&D platform, the compa

### [Huahaipharm: Fluvastatin Sodium Sustained-Release Tablets and Pimecrolimus Cream Obtained Drug Registration Certificates](https://longbridge.com/en/news/284185540.md)
*2026-04-27T09:24:28.000Z*
> Huahaipharm recently obtained the drug registration certificates for Fluvarstatin Sodium Sustained-Release Tablets and P

### [Net profit plummets by 76% behind: Is Huahai Pharmaceutical not falling behind, but rather changing lanes to overtake?](https://longbridge.com/en/news/283083598.md)
*2026-04-17T02:58:12.000Z*
> Huahaipharm's 2025 annual performance report shows that the total revenue was 8.586 billion yuan, a year-on-year decline

### [Huahaipharm is expected to turn a profit in the first quarter compared to the previous quarter, as the raw material pharmaceutical industry welcomes a recovery?](https://longbridge.com/en/news/282811590.md)
*2026-04-15T08:44:13.000Z*
> Huahaipharm expects to achieve a net profit attributable to the parent company of RMB 387 million to RMB 440 million in 

### [A-share lightning rod: Huahaipharm's first-quarter net profit excluding non-recurring items significantly declined, and Yara International clarified that rumors about the injection of coal chemical assets by shareholders are false](https://longbridge.com/en/news/282761052.md)
*2026-04-15T00:52:23.000Z*
> Huahaipharm expects its non-net profit in the first quarter of 2026 to decline by approximately 42% to 60% year-on-year,

### [Huahaipharm issued a profit forecast, expecting a year-on-year increase of approximately 30% to 48% in net profit attributable to the parent company for the first quarter](https://longbridge.com/en/news/282689150.md)
*2026-04-14T12:14:07.000Z*
> Huahaipharm expects a year-on-year increase of approximately 30% to 48% in net profit attributable to the parent company

### [Huahaipharm: Net profit of 267 million yuan in 2025, a year-on-year decrease of 76.14%](https://longbridge.com/en/news/282677686.md)
*2026-04-14T11:00:32.000Z*
> Huahaipharm released its performance preliminary report for 2025, with operating revenue of 8.586 billion yuan, a year-o